oscar health inc - OSCR
OSCR
Close Chg Chg %
27.90 0.57 2.03%
Open Market
28.47
+0.57 (2.03%)
Volume: 2.05M
Last Updated:
Aug 10, 2026, 11:59 AM EDT
Company Overview: oscar health inc - OSCR
OSCR Key Data
| Open $27.25 | Day Range 27.25 - 28.88 |
| 52 Week Range 10.69 - 33.10 | Market Cap $9.27B |
| Shares Outstanding 301.49M | Public Float 244.03M |
| Beta 2.36 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.39 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.97M |
OSCR Performance
| 1 Week | 0.00% | ||
| 1 Month | -8.64% | ||
| 3 Months | 30.92% | ||
| 1 Year | 80.47% | ||
| 5 Years | 89.80% |
OSCR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 25.182 | |
| Number of Ratings | 12 | Current Quarters Estimate | -0.246 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 1.103 | |
| Last Quarter’s Earnings | 0.38 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.69 | Next Fiscal Year Estimate | 1.558 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 10 | 10 |
| Mean Estimate | -0.25 | -1.31 | 1.10 | 1.56 |
| High Estimates | 0.00 | -0.70 | 1.49 | 2.25 |
| Low Estimate | -0.53 | -1.92 | 0.75 | 1.00 |
| Coefficient of Variance | -66.63 | -28.30 | 21.21 | 21.78 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 2 | 2 | 1 |
| HOLD | 7 | 7 | 7 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Oscar Health Inc - OSCR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Oscar Health Inc - OSCR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 14, 2026 | Siddhartha Sankaran Director | 2,061 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 14, 2026 | David Alexander Plouffe Director | 7,535 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 14, 2026 | William J. Gassen Director | 7,071 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 14, 2026 | Jeffery H. Boyd Director | 69,858 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 10,196,877 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 9,196,876 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.92 per share | 109,626,761.92 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | 10,196,876 | Open market or private purchase of non-derivative security Non-derivative transaction at $11.92 per share | 121,546,761.92 |
| Apr 8, 2026 | Mark T. Bertolini Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |